Arbutus Biopharma (ABUS) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 81.3% versus a gain of 0.0%. Over five years, ABUS leads with a +2.5% price change compared with -55.0% for SLN. Arbutus Biopharma is the larger company by market cap ($640.7 million vs $591.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | SLN |
|---|---|---|
| Share price | $4.18 | $9.52 |
| Market cap | $640.69M | $591.71M |
| 1-day change | -2.56% | -3.05% |
| YTD return | -13.10% | +56.58% |
| 1-year return | 0.00% | +81.33% |
| 5-year return | +2.45% | -55.00% |
| P/E ratio (TTM) | 5.29 | — |
| EPS (TTM) | $0.79 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $17.58 |
| 52-week low | $3.50 | $4.19 |
| Distance from 52-week high | -23.30% | -45.84% |
| Analyst consensus | none | buy |
| Avg. price target upside | +27.99% | +246.64% |
| Average volume | 4.71M | 1.12M |
| Shares outstanding | 153.28M | 62.15M |
| Employees | 19 | 88 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed ABUS by 81.3 percentage points over the past year.
- The two companies sit in different sectors: Arbutus Biopharma in Health Care and Silence Therapeutics Plc American Depository Share in Healthcare.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Healthcare · Biotechnology · 88 employees
ABUS vs SLN FAQ
Which is bigger, Arbutus Biopharma or Silence Therapeutics Plc American Depository Share?
Arbutus Biopharma (ABUS) is larger, with a market capitalization of $640.69M compared with $591.71M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, ABUS or SLN?
SLN returned +81.33% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Silence Therapeutics Plc American Depository Share in the same industry?
No. Arbutus Biopharma is in the Health Care sector, while Silence Therapeutics Plc American Depository Share is in Healthcare.